-
Subject Areas on Research
-
A controlled trial of long-term administration of intravenous immunoglobulin to prevent late infection and chronic graft-vs.-host disease after marrow transplantation: clinical outcome and effect on subsequent immune recovery.
-
A phase 1/2 study of an adjuvanted varicella-zoster virus subunit vaccine in autologous hematopoietic cell transplant recipients.
-
A phase 2 trial of the somatostatin analog pasireotide to prevent GI toxicity and acute GVHD in allogeneic hematopoietic stem cell transplant.
-
A single institutional review of pediatric Bacillus spp. bloodstream infections demonstrates increased incidence among children with cancer.
-
Addressing End-of-Life Quality Gaps in Hematologic Cancers: The Importance of Early Concurrent Palliative Care.
-
Adherence to Measuring What Matters Items When Caring for Patients With Hematologic Malignancies Versus Solid Tumors.
-
Adult recipients of umbilical cord blood transplants after nonmyeloablative preparative regimens.
-
Advance Care Planning and Palliative Care Specialists in Malignant Hematology and Stem-Cell Transplantation: On Why It Takes A Village.
-
Alemtuzumab for the prevention and treatment of graft-versus-host disease.
-
Allogeneic Transplantation after Myeloablative Rituximab/BEAM ± Bortezomib for Patients with Relapsed/Refractory Lymphoid Malignancies: 5-Year Follow-Up Results.
-
Altered B-cell homeostasis and excess BAFF in human chronic graft-versus-host disease.
-
An aberrant NOTCH2-BCR signaling axis in B cells from patients with chronic GVHD.
-
Apoptosis in haematological malignancies.
-
Apoptosis signaling and BCL-2 pathways provide opportunities for novel targeted therapeutic strategies in hematologic malignances.
-
Applications of Gene Editing Technologies to Cellular Therapies.
-
Association between high-density lipoprotein cholesterol level and risk of hematologic malignancy.
-
Association of Chronic Graft-versus-Host Disease with Late Effects following Allogeneic Hematopoietic Cell Transplantation for Children with Hematologic Malignancy.
-
Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic/myeloproliferative neoplasms.
-
B cells from patients with chronic GVHD are activated and primed for survival via BAFF-mediated pathways.
-
B cells in chronic graft-versus-host disease.
-
Blastic Plasmacytoid Dendritic Cell Neoplasm: Progress in Cell Origin, Molecular Biology, Diagnostic Criteria and Therapeutic Approaches.
-
Blastic plasmacytoid dendritic cell neoplasm: a clinicopathologic review.
-
Bone density loss after allogeneic hematopoietic stem cell transplantation: a prospective study.
-
Breakthrough invasive fungal infections: Who is at risk?
-
Bronchoalveolar lavage Aspergillus Galactomannan lateral flow assay versus Aspergillus-specific lateral flow device test for diagnosis of invasive pulmonary Aspergillosis in patients with hematological malignancies.
-
CD4+/CD56+ hematodermic neoplasm: presentation of 2 cases and review of the concept of an uncommon tumor originated in plasmacytoid dendritic cells expressing CD123 (IL-3 receptor alpha).
-
Cancer Therapy-associated Lymphoproliferative Disorders: An Under-recognized Type of Immunodeficiency-associated Lymphoproliferative Disorder.
-
Cancer and pregnancy: the clinician's perspective.
-
Carbon monoxide diffusion capacity: how low can you go for hematopoietic cell transplantation eligibility?
-
Carcinogenicity of gasoline: a review of epidemiological evidence.
-
Centralized patient-reported outcome data collection in transplantation is feasible and clinically meaningful.
-
Checkpoint inhibitors in hematological malignancies.
-
Chromosome-Specific Human Herpesvirus 6 Integration and Hematologic Malignancies.
-
Clinical characteristics and outcomes of invasive Lomentospora prolificans infections: Analysis of patients in the FungiScope® registry.
-
Clinical effectiveness of posaconazole versus fluconazole as antifungal prophylaxis in hematology-oncology patients: a retrospective cohort study.
-
Clinicians' Understanding of Preferences and Values of People with Hematological Malignancies at the End of Life: Concurrent Surveys.
-
Combination of antisense oligonucleotide and low-dose chemotherapy in hematological malignancies.
-
Community health status and outcomes after allogeneic hematopoietic cell transplantation in the United States.
-
Comparison of High Doses of Total Body Irradiation in Myeloablative Conditioning before Hematopoietic Cell Transplantation.
-
Compound GW506U78 in refractory hematologic malignancies: relationship between cellular pharmacokinetics and clinical response.
-
Contextual tumor suppressor function of T cell death-associated gene 8 (TDAG8) in hematological malignancies.
-
Control of plasma uric acid in adults at risk for tumor Lysis syndrome: efficacy and safety of rasburicase alone and rasburicase followed by allopurinol compared with allopurinol alone--results of a multicenter phase III study.
-
Conventional Cytogenetic Analysis of Hematologic Neoplasms: A 20-Year Review of Proficiency Test Results From the College of American Pathologists/American College of Medical Genetics and Genomics Cytogenetics Committee.
-
Current and future perspectives on allogeneic transplantation using ex vivo expansion or manipulation of umbilical cord blood cells.
-
Cyclosporine or cyclosporine plus methylprednisolone for prophylaxis of graft-versus-host disease: a prospective, randomized trial.
-
Decisional involvement and information preferences of patients with hematologic malignancies.
-
Decreased Mortality in 1-Year Survivors of Umbilical Cord Blood Transplant vs. Matched Related or Matched Unrelated Donor Transplant in Patients with Hematologic Malignancies.
-
Differential impact of inhibitory and activating Killer Ig-Like Receptors (KIR) on high-risk patients with myeloid and lymphoid malignancies undergoing reduced intensity transplantation from haploidentical related donors.
-
Disparities in place of death for patients with hematological malignancies, 1999 to 2015.
-
Do We Need Full Donor Chimerism? How Alloreactive Cell Therapies without Substantial Engraftment Might Treat Hematologic Cancers.
-
Early Palliative Care Services and End-of-Life Care in Medicare Beneficiaries with Hematologic Malignancies: A Population-Based Retrospective Cohort Study.
-
Early Palliative Care for Patients with Hematologic Malignancies: Is It Really so Difficult to Achieve?
-
Effect of Inpatient Palliative Care During Hematopoietic Stem-Cell Transplant on Psychological Distress 6 Months After Transplant: Results of a Randomized Clinical Trial.
-
Effect of Inpatient Palliative Care on Quality of Life 2 Weeks After Hematopoietic Stem Cell Transplantation: A Randomized Clinical Trial.
-
Efficacy and safety of ex vivo cultured adult human mesenchymal stem cells (Prochymal™) in pediatric patients with severe refractory acute graft-versus-host disease in a compassionate use study.
-
End-of-life care quality outcomes among Medicare beneficiaries with hematologic malignancies.
-
Endogenous oncogenic Nras mutation initiates hematopoietic malignancies in a dose- and cell type-dependent manner.
-
Epidemiological and mycological characteristics of candidemia in patients with hematological malignancies attending a tertiary-care center in India.
-
Fractionated total-body irradiation, etoposide, and cyclophosphamide followed by allogeneic bone marrow transplantation for patients with high-risk or advanced-stage hematological malignancies.
-
Gene dose-dependent control of hematopoiesis and hematologic tumor suppression by CBP.
-
Health-Related Quality of Life Following Allogeneic Hematopoietic Cell Transplantation with Omidubicel versus Umbilical Cord Blood.
-
Hemato-oncology and palliative care teams: is it time for an integrated approach to patient care?
-
Heparan sulfate, an endogenous TLR4 agonist, promotes acute GVHD after allogeneic stem cell transplantation.
-
Histiocytic Neoplasms, Version 2.2021, NCCN Clinical Practice Guidelines in Oncology.
-
How Caregivers Cope and Adapt When a Family Member Is Diagnosed With a Hematologic Malignancy: Informing Supportive Care Needs.
-
How I treat refractory chronic graft-versus-host disease.
-
How we manage grief.
-
Ibrutinib: a new targeted therapy for hematologic cancers.
-
Immune checkpoint blockade: Releasing the brake towards hematological malignancies.
-
Impact of Early Palliative Care on End-of-Life Outcomes in Hematologic Malignancies.
-
Impact of a Hematologic Malignancy Diagnosis and Treatment on Patients and Their Family Caregivers.
-
Impact of exercise on the immune system and outcomes in hematologic malignancies.
-
Improving Transitional Care: The Role of Handoffs and Discharge Checklists in Hematologic Malignancies.
-
Indications and donor selections for allogeneic stem cell transplantation in children with hematologic malignancies.
-
Influence of age on the outcome of 500 autologous bone marrow transplant procedures for hematologic malignancies.
-
Inhibiting the palmitoylation/depalmitoylation cycle selectively reduces the growth of hematopoietic cells expressing oncogenic Nras.
-
Integrative gene expression profiling reveals G6PD-mediated resistance to RNA-directed nucleoside analogues in B-cell neoplasms.
-
Itraconazole and antiretroviral therapy: strategies for empirical dosing - Author's reply.
-
Itraconazole and antiretroviral therapy: strategies for empirical dosing.
-
Late cardiovascular morbidity and mortality following pediatric allogeneic hematopoietic cell transplantation.
-
Lean Into the Uncomfortable: Using Trauma-Informed Care to Engage in Shared Decision-Making With Racial Minorities With Hematologic Malignancies.
-
Leveraging Natural Killer Cell Innate Immunity against Hematologic Malignancies: From Stem Cell Transplant to Adoptive Transfer and Beyond.
-
Limited Tissue Biopsies and Hematolymphoid Neoplasms.
-
Linker for activation of T cells (LAT), a novel immunohistochemical marker for T cells, NK cells, mast cells, and megakaryocytes: evaluation in normal and pathological conditions.
-
Longitudinal Toxicity over Time (ToxT) analysis to evaluate tolerability: a case study of lenalidomide in the CALGB 50401 (Alliance) trial.
-
Malignant (Diffuse) Mesothelioma in Patients With Hematologic Malignancies: A Clinicopathologic Study of 45 Cases.
-
Management of adverse events associated with idelalisib treatment: expert panel opinion.
-
Mechanisms of Therapeutic Antitumor Monoclonal Antibodies.
-
Monoclonal antibodies as targeted therapy in hematologic malignancies in older adults.
-
Morphologic examination of sequential bone marrow biopsies after nonmyeloablative stem cell transplantation complements molecular studies of donor engraftment.
-
Omidubicel vs standard myeloablative umbilical cord blood transplantation: results of a phase 3 randomized study.
-
Oncology Nurse Navigation: Development and Implementation of a Program at a Comprehensive Cancer Center
-
One-unit versus two-unit cord-blood transplantation for hematologic cancers.
-
One-unit versus two-unit cord-blood transplantation.
-
Optimal Practices in Unrelated Donor Cord Blood Transplantation for Hematologic Malignancies.
-
Palifermin for the reduction of acute GVHD: a randomized, double-blind, placebo-controlled trial.
-
Palliative and End-of-Life Care for Patients With Hematologic Malignancies.
-
Palliative and End-of-Life Care in Myelodysplastic Syndromes.
-
Palliative care and hematologic malignancies: old dog, new tricks?
-
Palliative care for patients with hematologic malignancies: are we meeting patients' needs early enough?
-
Palliative care in hematologic malignancies: a multidisciplinary approach.
-
Palliative care integration in haematological malignancies: towards a needs-based approach.
-
Pan-cancer Convergence to a Small-Cell Neuroendocrine Phenotype that Shares Susceptibilities with Hematological Malignancies.
-
Partially matched, nonmyeloablative allogeneic transplantation: clinical outcomes and immune reconstitution.
-
Patient-hematologist discordance in perceived chance of cure in hematologic malignancies: A multicenter study.
-
Perceptions of palliative care among hematologic malignancy specialists: a mixed-methods study.
-
Pharmacokinetics of nelarabine and 9-beta-D-arabinofuranosyl guanine in pediatric and adult patients during a phase I study of nelarabine for the treatment of refractory hematologic malignancies.
-
Phase 1 study of ixazomib, an investigational proteasome inhibitor, in advanced non-hematologic malignancies.
-
Phase I study of 506U78 administered on a consecutive 5-day schedule in children and adults with refractory hematologic malignancies.
-
Phase I/II Study of Stem-Cell Transplantation Using a Single Cord Blood Unit Expanded Ex Vivo With Nicotinamide.
-
Phase I/II Trial of Dose-Escalated Busulfan Delivered by Prolonged Continuous Infusion in Allogeneic Transplant Patients.
-
Physician communication styles in initial consultations for hematological cancer.
-
Pitfalls and Successes in Trials in Older Transplant Patients with Hematologic Malignancies.
-
Plasma microRNA signature as a noninvasive biomarker for acute graft-versus-host disease.
-
Plerixafor (a CXCR4 antagonist) following myeloablative allogeneic hematopoietic stem cell transplantation enhances hematopoietic recovery.
-
Plerixafor alone for the mobilization and transplantation of HLA-matched sibling donor hematopoietic stem cells.
-
Post-transplantation B cell activating factor and B cell recovery before onset of chronic graft-versus-host disease.
-
Pre-engraftment syndrome after myeloablative dual umbilical cord blood transplantation: risk factors and response to treatment.
-
Preexisting melanoma and hematological malignancies, prognosis, and timing to solid organ transplantation: A consensus expert opinion statement.
-
Prevalence and Etiology of Community-acquired Pneumonia in Immunocompromised Patients.
-
Prevention of GVHD without losing GVL effect: windows of opportunity.
-
Quality of life in higher resolution: the next generation of comparative effectiveness research in malignant hematology.
-
RAS signaling promotes resistance to JAK inhibitors by suppressing BAD-mediated apoptosis.
-
Randomized clinical trials for hematopoietic stem cell transplantation: lessons to be learned from the European experience.
-
Randomized, double-blind trial of fluconazole versus voriconazole for prevention of invasive fungal infection after allogeneic hematopoietic cell transplantation.
-
Real-world effectiveness of antifungal prophylaxis with posaconazole as the primary agent in patients with haematological malignancies.
-
Reduced-intensity allogeneic transplantation using alemtuzumab from HLA-matched related, unrelated, or haploidentical related donors for patients with hematologic malignancies.
-
Reduced-intensity conditioning allogeneic hematopoietic cell transplantation for patients with hematologic malignancies who relapse following autologous transplantation: a multi-institutional prospective study from the Cancer and Leukemia Group B (CALGB trial 100002).
-
Reflections on and future of hematologic malignancies research in the Veterans Health Administration.
-
Regionalization of stem cell transplant procedures into teaching hospitals in United States: are we ready?
-
Reply to J. Schildmann et al.
-
Response and toxicity of donor lymphocyte infusions following T-cell depleted non-myeloablative allogeneic hematopoietic SCT from 3-6/6 HLA matched donors.
-
Results of the Cord Blood Transplantation Study (COBLT): clinical outcomes of unrelated donor umbilical cord blood transplantation in pediatric patients with hematologic malignancies.
-
Review of the patient-centered communication landscape in multiple myeloma and other hematologic malignancies.
-
Risk factors for acute GVHD and survival after hematopoietic cell transplantation.
-
Role of transforming growth factor-beta in hematologic malignancies.
-
Rural-urban disparities in place of death in hematologic malignancies in the United States, 2003 to 2019.
-
SARS-CoV-2 vaccine safety and immunogenicity in patients with hematologic malignancies, transplantation, and cellular therapies.
-
Severe pulmonary toxicity after myeloablative conditioning using total body irradiation: an assessment of risk factors.
-
Small-molecule nicotinamide for ex vivo expansion of umbilical cord blood.
-
Surgical Management of Non-small Cell Lung Cancer with Solitary Hematogenous Metastases.
-
Survival after HLA-identical allogeneic peripheral blood stem cell and bone marrow transplantation for hematologic malignancies: meta-analysis of randomized controlled trials.
-
Symptom burden of haematological malignancies as death approaches in a community palliative care service: a retrospective cohort study of a consecutive case series.
-
T-Cell recovery in adults and children following umbilical cord blood transplantation.
-
The 5th edition of the World Health Organization Classification of Haematolymphoid Tumours: Lymphoid Neoplasms.
-
The Diagnostic Yield of Site and Symptom-Based Biopsies for Acute Gastrointestinal Graft-Versus-Host Disease: A 5-Year Retrospective Review.
-
The Surprise Question and Identification of Palliative Care Needs among Hospitalized Patients with Advanced Hematologic or Solid Malignancies.
-
The Use of Indwelling Tunneled Pleural Catheters for Recurrent Pleural Effusions in Patients With Hematologic Malignancies: A Multicenter Study.
-
The copper chelator ATN-224 induces peroxynitrite-dependent cell death in hematological malignancies.
-
The relationship between methylenetetrahydrofolate reductase polymorphism and hematological malignancy.
-
The role of adenotonsillectomy in graft-versus-host disease.
-
The vascular niche: home for normal and malignant hematopoietic stem cells.
-
Thioredoxin and hematologic malignancies.
-
Top Ten Tips Palliative Care Clinicians Should Know About Caring for Patients with Hematologic Malignancies.
-
Transfer of allogeneic CD62L- memory T cells without graft-versus-host disease.
-
Umbilical cord blood expansion with nicotinamide provides long-term multilineage engraftment.
-
Umbilical cord blood transplantation in adults: results of the prospective Cord Blood Transplantation (COBLT).
-
Unique abnormalities of CD4(+) and CD8(+) central memory cells associated with chronic graft-versus-host disease improve after extracorporeal photopheresis.
-
Universal Mask Usage for Reduction of Respiratory Viral Infections After Stem Cell Transplant: A Prospective Trial.
-
Unlicensed Umbilical Cord Blood Units Provide a Safe and Effective Graft Source for a Diverse Population: A Study of 2456 Umbilical Cord Blood Recipients.
-
Using Interleukin 6 and 8 in Blood and Bronchoalveolar Lavage Fluid to Predict Survival in Hematological Malignancy Patients With Suspected Pulmonary Mold Infection.
-
Utility of CT assessment in hematology patients with invasive aspergillosis: a post-hoc analysis of phase 3 data.
-
Venous Thromboembolism Risk Assessment and Prophylaxis Use in Pediatric, Adolescent, and Young Adult Hematology Oncology Patients.
-
Voriconazole in the treatment of aspergillosis, scedosporiosis and other invasive fungal infections in children.
-
What is different about patients with hematologic malignancies? A retrospective cohort study of cancer patients referred to a hospice research network.
-
When and why should patients with hematologic malignancies see a palliative care specialist?
-
hemaClass.org: Online One-By-One Microarray Normalization and Classification of Hematological Cancers for Precision Medicine.
-
t(11;16)(q23;p13)/KMT2A-CREBBP in hematologic malignancies: presumptive evidence of myelodysplasia or therapy-related neoplasm?
-
Keywords of People
-
-
Chen, Jun,
Professor of Medicine,
Duke Cancer Institute
-
Craciunescu, Oana,
Professor of Radiation Oncology,
Radiation Oncology
-
Dement, John McCray,
Professor Emeritus in Family Medicine and Community Health,
Family Medicine & Community Health,Occupational & Environmental Medicine
-
Doan, Phuong Linh,
Associate Professor of Medicine,
Duke Cancer Institute
-
Lagoo, Anand Shreeram,
Professor of Pathology,
Pathology
-
LeBlanc, Thomas William,
Associate Professor of Medicine,
Duke Cancer Institute
-
Tsalik, Ephraim,
Adjunct Associate Professor in the Department of Medicine,
Medicine, Infectious Diseases